RXRX · Recursion Pharmaceuticals, Inc.

Track RXRX — free

$3.20 +0.04 (+1.27%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$1.69B

535.34M

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 8 wks

Latest filing: 10-Q

filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$54.85M

Trailing 12 months

Net income (TTM)

−$518.88M

Trailing 12 months

Revenue growth YoY

-60.1%

Year over year

Operating margin

-991.7%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-20.8%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+27.6%

Year over year · more shares

Price change (1Y)

-30.4%

Trailing year

Short interest

33.5%

Latest settlement · 10.6 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.60

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −12%

below

Price vs 50-day avg −3%

below

RSI (14) 46

neutral

MACD trend Negative

52-week position 9%

near low

Momentum

relative strength

Very Weak

1-month return −3%

trailing

6-month return −2%

trailing

YTD return −22%

this year

Relative strength −19%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $3 › 200d $4 — 200d above 50d

Institutional flow Accumulating

+2% holders QoQ · +53 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

33.46% of float · ▲ +0.7% MoM · 10.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

348 holders — near 3-yr high, broad support

Squeeze score 76

high risk · 0–100

Fundamentals

Strong

Revenue growth +27%

Y/Y

EPS growth +15%

Y/Y

Free cash flow $-378.3M

Balance sheet $284.4M

net cash

Quant / Vol

risk profile

Very High

Volatility 72%

annualized · 1-yr

Max drawdown −58%

past year

ATR 5.9%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed May 6, 2026

Cash opex · 2026 Non-GAAP up to $390M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

3 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−12% Bearish

Price vs 50-day avg

−3% Neutral

RSI (14)

46 Neutral

MACD trend

Negative Bearish

52-week position

9% Bearish

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $3 › 200d $4 — 200d above 50d

Institutional flow Accumulating

+2% holders QoQ · +53 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

33.46% of float · ▲ +0.7% MoM · 10.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

348 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $3 Now $3 · 9% Range high $7

vs 200-day avg -12% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
RXRX Recursion Pharmaceuticals, Inc. this stock	$1.69B	-21.8%	+26.9%	—	33.5%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.40B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$81.67B	+1.2%	+20.8%	19.6	2.5%
ARGX Argenx SE	$61.60B	+17.1%	—	—	2.0%
CSLLY Csl Ltd	$57.41B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

348

% held: 69.3%
Net QoQ: +27.5M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

182

View

Short & Settlement

Short Interest Rising

Shares short

179.1M

Days to cover: 10.6d
Change: +1.2M sh

View

Short Volume

Short vol %

60%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

37.1K

Value: $122.7K
As of: Aug 14, 2026

View

Off-Exchange

Off-exchange %

48.4%

Week of: Aug 3, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$74.7M

Net income (FY): $-644.8M
EPS diluted: $-1.44

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 5, 2026
This year: 12

View

Proposed Sales

Value

$100.2K

Shares: 30.0K
Filed: Sep 1, 2026

View

Exempt Offerings

Offering

$245.9M

Filed: Nov 12, 2020

View

Earnings & Events

Earnings Calls Upcoming

Next call

Sep 15, 2026

Last call: Aug 5, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
RXRX	-7.0%	-3.3%	-1.5%	-5.9%	-21.8%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-5.8%	-1.6%	-19.4%	-5.5%	-33.8%

Key facts CIK 1601830 CUSIP 75629V104 13F (30d) 133 filings 133 filers Visit website Investor relations

RXRX · Recursion Pharmaceuticals, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance